Cell Genesys terminates Ph III trial of prostate cancer immunotherapy and slashes staff
This article was originally published in Scrip
Executive Summary
Cell Genesyswill place on hold the further development of GVAX immunotherapy for prostate cancer, its lead developmental candidate, pending a review of the programme with its collaboratorTakeda, and dramatically reduce its staff after the failure of a second Phase III pivotal trial. It said it would consider appropriate strategic alternatives for the company, which it plans to do in an "expeditious manner".